GeneDx Holdings Corp. heads into its June 18 earnings date carrying two conflicting signals: its biggest institutional backers are aggressively buying the stock at post-crash prices, while short sellers are adding to a position that now covers more than a quarter of the free float.
The insider story is the most striking feature of this setup. Corvex Management and Casdin Capital — the two largest institutional holders, together controlling roughly 28% of shares — have spent the past two weeks buying heavily into weakness. Casdin alone purchased 500,000 shares across three sessions in mid-May, spending close to $21.5 million. Corvex added more than 330,000 shares over the same window. Net buying across the past 90 days totals over 2 million shares at a combined value of roughly $83.9 million. These are board-represented holders buying at prices 40-50% below where the stock was trading in early 2026 — a signal of conviction, not routine portfolio management.
Short sellers are reading the situation differently. Short interest jumped 19.5% in a single week to 26.4% of the free float, a level that is genuinely crowded for a stock in the health care services sector. The week-on-week move from roughly 22% to 26% came entirely after late May, marking the sharpest one-week build in at least six weeks. That follows a catastrophic Q1 print on May 4 — the stock fell 47% in a single session, then shed another 8% over the following week, landing at lows that Corvex and Casdin evidently treated as an entry point. The short score sits at 63.2, a moderately elevated but stable reading that suggests bearish conviction is firm rather than accelerating into new territory. Cost to borrow has actually eased slightly, down around 3% on the week to 0.44% annualised — consistent with borrow being plentiful. Availability is at 313%, meaning there are roughly three shares available to lend for every one already borrowed. Shorts face no mechanical squeeze pressure from the lending market.
Options paint a bullish near-term picture. The put/call ratio has dropped to 0.36, comfortably below its 20-day average of 0.42 — indicating more call activity relative to puts than usual. That is a shift worth noting given where it was in early May, when the PCR was running above 0.6 in the immediate aftermath of the guidance cut. The drift lower over the past three weeks suggests options traders have pivoted toward a recovery thesis, at least in the near term. GH, the closest genomics peer in the dataset, gained 8.6% on the week, which may be providing some sector tailwind for that positioning.
The Street is split but leans bullish — with heavily reset price targets. Multiple firms cut targets sharply after the Q1 miss, with Wells Fargo slashing from $155 to $75 and Guggenheim dropping from $100 to $70, both on May 5. All major analysts maintained Buy or Overweight ratings. The consensus mean target sits near $77, implying roughly 45% upside from the current price of $53.13. That gap is real but should be read in context: the same analysts had targets at $155-$170 just months ago, and the stock trades at 91x trailing earnings and 68x EV/EBITDA on a PE that has expanded 39 points in 30 days purely because the denominator shrank. The bull case centres on GeneDx's dominant position in rare-disease exome and genome sequencing for pediatric patients, and the long-term scale of that market. Bears point to execution risk, weakening test volume growth, and a business that is still burning cash despite its revenue ramp.
The company's earnings history sets an uncomfortable backdrop. The last two quarterly prints produced a one-day move of -47% and -5% respectively, with the five-day follow-through extending both declines further. Law firms have been publicly investigating claims on behalf of shareholders since May, adding an overhang that typically keeps institutional participation cautious ahead of a catalyst. The securities litigation risk — a routine feature after a large guidance cut — has not deterred Corvex and Casdin, but it may be contributing to the parallel build in short interest. The most important question heading into June 18 is whether management's revised guidance holds, and whether test volume trends have stabilised after the Q1 disappointment.
See the live data behind this article on ORTEX.
Open WGS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
